Kelly Bailey 1 , Carrye Cost 2 , Ian Davis 3 , Julia Glade-Bender 4 , Patrick Grohar 5 , Peter Houghton 6 , Michael Isakoff 7 , Elizabeth Stewart 8 , Nadia Laack 9 , Jason Yustein 10 , Damon Reed 11 , 12 , Katherine Janeway 13 , Richard Gorlick 14 , Stephen Lessnick 15 , 16 , Steven DuBois 13 , Pooja Hingorani a , 17
15 April 2019
Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.